Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 502-505

  Persson, M ^a,b   Engstrom G ^a   Bjorkbacka H ^a   Hedblad, B ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Inflammation; Soluble urokinase plasminogen activator receptor

Indexed keywords

C REACTIVE PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DIET; DIET SURVEYS; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SWEDEN; TIME FACTORS;

EID: 84855940788     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.039     Document Type: Article

References (25)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine 2005, 352(16):1685-1695.
2. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
3. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry 2008, 54(1):24-38.
4. Wilson P.W. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation 2004, 110(25):e568-e571.
5. Kofoed K., Schneider U.V., Scheel T., Andersen O., Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clinical Chemistry 2006, 52(7):1284-1293.
6. Riisbro R., Christensen I.J., Hogdall C., Brunner N., Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. The International Journal of Biological Markers 2001, 16(4):233-239.
7. Sidenius N., Sier C.F., Ullum H., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96(13):4091-4095.
8. Ostrowski S.R., Ullum H., Goka B.Q., et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. The Journal of Infectious Diseases 2005, 191(8):1331-1341.
9. Sier C.F., Stephens R., Bizik J., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Research 1998, 58(9):1843-1849.
10. de Bock C.E., Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Medical Care Research Review 2004, 24(1):13-39.
11. Eugen-Olsen J., Andersen O., Linneberg A., et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. Journal of Internal Medicine 2010, 268(3):296-308.
12. Sehestedt T., Lyngbaek S., Eugen-Olsen J., et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011.
13. Berglund G., Elmstahl S., Janzon L., Larsson S.A. The Malmö Diet and Cancer Study. Design and feasibility. Journal of Internal medicine 1993, 233(1):45-51.
14. Rosvall M., Janzon L., Berglund G., Engstrom G., Hedblad B. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 2005, 179(2):325-331.
15. Rosvall M., Ostergren P.O., Hedblad B., Isacsson S.O., Janzon L., Berglund G. Occupational status, educational level, and the prevalence of carotid atherosclerosis in a general population sample of middle-aged Swedish men and women: results from the Malmö Diet and Cancer Study. American Journal of Epidemiology 2000, 152(4):334-346.
16. Persson M., Nilsson J.A., Nelson J.J., Hedblad B., Berglund G. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007, 190(2):388-396.
17. Evaluation of quality of diagnosis of acute myocardial infarction, inpatient register 1997 and 1995. In: Welfare TNBoHa, editors. The National Board of Health and Welfare; 2000.
18. Engstrom G., Jerntorp I., Pessah-Rasmussen H., Hedblad B., Berglund G., Janzon L. Geographic distribution of stroke incidence within an urban population: relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke: A Journal of Cerebral Circulation 2001, 32(5):1098-1103.
19. Zia E., Hedblad B., Pessah-Rasmussen H., Berglund G., Janzon L., Engstrom G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke: A Journal of Cerebral Circulation 2007, 38(10):2681-2685.
20. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J., Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clinic Proceedings 2007, 82(2):159-165.
21. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2006.
22. Andersen O., Eugen-Olsen J., Kofoed K., Iversen J., Haugaard S.B. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. Journal of Medical Virology 2008, 80(2):209-216.
23. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nature Reviews Molecular Cell Biology 2002, 3(12):932-943.
24. Manjer J., Carlsson S., Elmstahl S., et al. The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. European Journal of Cancer Prevention 2001, 10(6):489-499.
25. Manjer J., Elmstahl S., Janzon L., Berglund G. Invitation to a population-based cohort study: differences between subjects recruited using various strategies. Scandinavian Journal of Public Health 2002, 30(2):103-112.